CBU
ASND icon

CIBC Bancorp USA’s Ascendis Pharma A/S ASND Stock Holding History

CIBC Bancorp USA’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.24M Sell
8,398
-984
-10% -$230K ﹤0.01% 931
2026
Q1 		$2.15M Buy
+9,382
New +$2.1M ﹤0.01% 889

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

CIBC Bancorp USA's ASND Position: Q2 2026 in Review

CIBC Bancorp USA reduced its Ascendis Pharma A/S (ASND) stake by 10% in Q2 2026, selling an estimated $230K and leaving 8,398 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #931.

CIBC Bancorp USA first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • CIBC Bancorp USA held 8,398 shares of Ascendis Pharma A/S worth $2.24M as of Q2 2026.
  • CIBC Bancorp USA sold 984 Ascendis Pharma A/S shares in Q2 2026, an estimated $230K.
  • Ascendis Pharma A/S made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #931 holding.
  • CIBC Bancorp USA first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
  • 313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.